Three-dimensional whole-liver perfusion magnetic resonance imaging in patients with hepatocellular carcinomas and colorectal hepatic metastases

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Rao, Sheng Xiang ^a   Chen, Cai Zhong ^a   Liu, Hao ^a   Zeng, Meng Su ^a   Qu, Xu Dong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

3D Magnetic Resonance Imaging; Colorectal hepatic metastasis; HCC; Inter observer analysis; Perfusion Imaging

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORPHOLOGY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COLORECTAL HEPATIC METASTASIS; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; LIMIT OF DETECTION; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; PERFUSION WEIGHTED IMAGING; QUANTITATIVE ANALYSIS; THREE DIMENSIONAL IMAGING; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEASIBILITY STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGING, THREE-DIMENSIONAL; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; OBSERVER VARIATION; STATISTICS, NONPARAMETRIC;

EID: 84875286919     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-53     Document Type: Article

References (22)

1. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion imaging of the liver: current challenges and future goals. Radiology 2005, 234(3):661-673. 10.1148/radiol.2343031362, 15734925.
2. Schirin-Sokhan R, Winograd R, Roderburg C. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol 2012, 18(6):541-545. 10.3748/wjg.v18.i6.541, 3280399, 22363120.
3. Goetti R, Leschka S, Desbiolles L. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Invest Radiol 2010, 45(7):419-426.
4. Ng CS, Chandler AG, Wei W. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011, 260(3):762-770. 10.1148/radiol.11110331, 3156998, 21788525.
5. Ng CS, Raunig DL, Jackson EF, Ashton EA, Kelcz F, Kim KB, Kurzrock R, McShane TM. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 2010, 194(2):W134-140. 10.2214/AJR.09.3116, 20093564.
6. Koh TS, Thng CH, Lee PS, Hartono S, Rumpel H, Goh BC, Bisdas S. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 2008, 249(1):307-320. 10.1148/radiol.2483071958, 18695207.
7. Morgan B, Thomas AL, Drevs J. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21(21):3955-3964. 10.1200/JCO.2003.08.092, 14517187.
8. Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA, Taouli B. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 2008, 246(3):926-934. 10.1148/radiol.2463070077, 18195377.
9. Tofts PS, Brix G, Buckley DL. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10(3):223-332. 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S, 10508281.
10. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007, 13((2 Pt 2):770s-776s.
11. Reitan NK, Thuen M, Goa PE, de Lange DC. Characterization of tumor microvascular structure and permeability: comparison between magnetic resonance imaging and intravital confocal imaging. J Biomed Opt 2010, 15(3):036004. 10.1117/1.3431095, 2902535, 20615006.
12. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002, 15(2):154-163. 10.1002/nbm.756, 11870911.
13. Galbraith SM, Lodge MA, Taylor NJ. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002, 15(2):132-142. 10.1002/nbm.731, 11870909.
14. Jackson A. Imaging microvascular structure with contrast enhanced MRI. Br J Radiol 2003, 76(2):S159-S173. 10.1259/bjr/22322389, 15572338.
15. Ueda T, Oda T, Kinoshita T. Neovascularization in pancreatic ductal adenocarcinoma: Microvessel count analysis, comparison with non-cancerous regions and other types of carcinomas. Oncol Rep 2002, 9(2):239-245.
16. Duarte IG, Bufkin BL, Pennington MF. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998, 115(3):652-658. 10.1016/S0022-5223(98)70331-9, 9535454.
17. Weidner N, Folkman J, Pozza F. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 16;84(24):1875-1887.
18. Vermeulen PB, Verhoeven D, Hubens G. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995, 6(1):59-64.
19. Goel S, Duda DG, Xu L. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91(3):1071-1121. 10.1152/physrev.00038.2010, 3258432, 21742796.
20. Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, Gillespie GY. High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med 2009, 61(3):615-625. 10.1002/mrm.21931, 3243360, 19235262.
21. Zhu AX, Sahani DV, Duda DG. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035. 10.1200/JCO.2008.20.9908, 2702235, 19470923.
22. Gaustad JV, Benjaminsen IC, Ruud EB, Rofstad EK. Dynamic contrast-enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions. J Magn Reson Imaging 2007, 26(1):133-143. 10.1002/jmri.20939, 17659570.